Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-10-11
2005-10-11
Borin, Michael (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S329000, C435S325000
Reexamination Certificate
active
06953779
ABSTRACT:
The clinical outcome of disseminated melanoma is grim. Small molecular weight antagonists (preferably about seven amino acid residues) specific for MCR on melanoma cells are provided for the therapy of melanoma as well as in other conditions where modulation of MCR is of clinical significance. A particularly preferred antagonist is p-anisoyl-[D-Arg6,9, D-Lys11, D-Leu12] dynorphin A(6-12)-NH2, which is an excellent antagonist of the MCR-1 receptor.
REFERENCES:
patent: 4016100 (1977-04-01), Suzuki et al.
patent: 4091090 (1978-05-01), Sipos
patent: 4348384 (1982-09-01), Horikoshi et al.
patent: 5126327 (1992-06-01), Takeuchi et al.
patent: 5480869 (1996-01-01), Wei et al.
patent: 5482930 (1996-01-01), Wei et al.
patent: 5514670 (1996-05-01), Friedman et al.
patent: 2193891 (1987-08-01), None
patent: WO 97/47316 (1997-12-01), None
Dooley et al. (1996) “New, Highly Active Orphanin Receptor Ligands Identified Using Combinatorial Libraries,” poster abstract from 27thMeeting of the International Narcotics Research Conference, abstract TU13, Long Beach, California, 1996.
Hadley et al. (1996) “Melanocortin Receptors: Identification and Characterization by Melanotropic Peptide Agonists and Antagonists,” Pgiment Cell Res., pp. 213-234.
Henderson and McKnight (1997) “The Orphan Opiod Receptor and Its Endogenous Ligand—Nociceptin/Orphanin FG,” Trends in Pharmacological Sciences, 18, pp. 293-300.
Ollmann et al. (1997) “Antagonism of Central Melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein,” Science, 278, pp. 135-138.
Quillan and Sadee (1997) “Dynorphin Peptides: Antagonists of Melanocortin Receptors,” Pharmaceutical Research, 14:6, pp. 713-719.
Siegrist and Eberle (1995) Melanocortins and Their Implication in Melanoma, TEM, 6:4, pp. 115-120.
Siegrist et al. (1997) “Interactions of α-Melanotropin and Agouti on B16 Melanoma Cells: Evidence for Inverse Agonism of Agouti,” J. Recept. Signal. Transduct. Res., 17, pp. 75-98.
Berge et al. (1977) “Pharmaceutical Salts,” J. Pharm. Sci., 66:1, pp. 1-19.
Yang et al. (1997) “Effects of Recombinant Agouti-Signaling Protein on Melanocortin Action,” Mol. Endocrinol., 11, pp. 274-2880.
Sawyer et al. (1989) Peptide Research, 2(1), 140-146.
Thomas et al. (1995) Peptides, 16(3), 547-50.
Vlasov et al. (1996) Proc. Eur. Pept. Symp., 24th, Meeting Date 1996, 877-878. Editors: Ramage, Robert; Epton, Roger, Publisher: Mayflower Scientific, Kingswinford, UK.
Dowdy et al. (1995) Photodermatol., Photoimmunol. Photomed., 11(4), 143-8.
Zhang et al. (1996) Chin. Med. Sci. J. 11(2)63-68.
Chang Jaw Kang
Quillan J. Mark
Sadee Wolfgang
Vlasov Guennady P.
Wei Edward T.
Borin Michael
Quine I. P. Law Group, P.C.
The Regents of the University of California
LandOfFree
Melanocortin receptor antagonists and modulations of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Melanocortin receptor antagonists and modulations of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanocortin receptor antagonists and modulations of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3477483